comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 04:45:15 - browse：345

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Diagnostic tests are hitting their mathematical limits

hotspot

WSS

CDC wastewater surveillance dashboard to track bird flu hotspots

Bird flu outbreak in cows is latest avian flu curveball

Bird flu outbreak in cows is latest avian flu curveball

How to improve immunocompromised access to mAb treatments

How to improve immunocompromised access to mAb treatments

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

leisure time

comprehensive

entertainment

New air purifier tech could be key to improving indoor air quality

Study: AI not yet building 'n

Medicare details structure of new drug price negotiation program

Mayo Clinic plans $5B tech

DIEP, the 'gold standard' of breast reconstruction, is under threat

UnitedHealth’s Optum accused of antitrust violations in California

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: brain research, obesity drug sales, Novartis

At least 13 dead in Texas as scorching temps continue

J&J to emphasize cancer drugs, stop much of its vaccine research

Wikipedia

Organ aging and disease risk measured by new blood test

What nurses really want: sufficient staffing for patient care

ReNAgade cuts staff seven months after raising $300 million

FDA investigates CAR

Sanofi strikes deal with Novavax, boosting the vaccine maker

How to improve immunocompromised access to mAb treatments

hotspot

explore

Wikipedia

hotspot